On March 31, 2022, the clinical trial application of ARB202 received ethics approval in Australia. ARB202 is an innovative bispecific antibody drug developed by AIM-HI Portfolio Company Arbele, a biotech company based in the Hong Kong Science and Technology Park.…
We're excited that Dr. Sujuan Ba, AIM-HI CEO & Co-Founder, is featured as one of the "20 Most Inspiring Women Leaders 2022" by THE WOMEN LEADERS Magazine. Read about her illustrious career leading three successful non-profits in the field of cancer…
Recently, Sujuan Ba, Ph.D., CEO & Co-Founder of the AIM-HI Accelerator Fund, was featured in the series Profiles in Success as a Scientist Trailblazing the Transformation. In the interview, Dr. Ba highlights her path from determined teen to research and eventually nonprofit leadership.…
by Cristina Campabadal In the last year and a half of the pandemic, we have become aware of the great importance of healthcare. And even more, after seeing hospitals all over the world saturated, even having to temporarily build others,…
The year 2021 saw an unprecedented triumph of science as the world witnessed the fastest vaccine development in history. That is the result of decades of investments in basic cancer research. The AIM-HI Accelerator Fund has made decisive progress in…
We have great news to share! The 2022 AIM-HI Women’s Venture Competition is Now Open for Applications! This unique funding program, now in its third year, provides investment, coaching, and networking opportunities to women-led oncology startups. Companies with a woman…
by Ronald DePinho, M.D. We just passed the 40th anniversary of the biotech industry, a birth made possible by the confluence of a seminal patent in recombinant DNA technology, the successful IPO of the first biotech company Genentech, validation of…
The AIM-HI Accelerator Fund is fiercely dedicated to accelerating the commercialization of innovative lab breakthroughs into life-saving new therapies and technologies. These words evoke a pathway. A pathway of progress that connects cancer research lab breakthroughs to game-changing novel technologies.…
The AIM-HI Accelerator Fund just announced 10 semi-finalists for the 2021 Women’s Venture Competition! These oncology companies have been selected from among an exceptional pool of applications submitted globally by women scientist-entrepreneurs. Decision making was led by a selection committee…
Tvardi Therapeutics, Inc. (“Tvardi”) a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, has closed a $74 million Series B financing. The financing was led by new investors Slate Path Capital, Palkon Capital, ArrowMark Partners, and…
